Sintilimab for Gastric Cancer, Lepodisiran Targeting Lipoprotein(a), CONSORT Extension for Factorial Trials, and more

JAMA Editor’s Summary

Sintilimab for Gastric Cancer, Lepodisiran Targeting Lipoprotein(a), CONSORT Extension for Factorial Trials, and more

Editor’s Summary by Preeti Malani, MD, MSJ, Deputy Editor of JAMA, the Journal of the American Medical Association, for the December 5, 2023, issue. Related Content:

December 5, 2023

Listen on your favorite player Take me to this show’s page

Newer →

Antithrombotic Regimens for LVADs, Cannabis in Pregnancy, Hepatitis C in Black Individuals, and more

← Older

Toripalimab for Nasopharyngeal Carcinoma, Cervical Cancer Screening Strategies, Obesity Review, and more

Facebook Twitter Buffer LinkedIn WhatsApp

Sintilimab for Gastric Cancer, Lepodisiran Targeting Lipoprotein(a), CONSORT Extension for Factorial Trials, and more

Editor’s Summary by Preeti Malani, MD, MSJ, Deputy Editor of JAMA, the Journal of the American Medical Association, for the December 5, 2023, issue. Related Content:

Listen on your favorite player

New to Podcasts? It's easy to get started!

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Join Our Newsletter

We gratefully acknowledge the many organizations that have generously supported our podcasts and platform.

Network Sponsors and Advertisers

Event and Media Partners

00:00

00:00